{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-050338","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.826836+00:00","generated_at":"2026-06-16T12:26:04.252501+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ReShape Lifesciences raises $2.5M via registered direct offering and private placement at $3.07/unit","bullets":["Entered into securities purchase agreement with institutional investor for 800,695 shares/pre-funded warrants at $3.07/unit, raising ~$2.5M gross.","Concurrent private placement of warrants to purchase 800,695 shares at $3.07, exercisable immediately, expire in 5.5 years.","Amended existing warrants for 164,656 shares from $15.00 to $3.07 exercise price effective upon closing.","Placement agent Maxim Group receives 7% cash fee and 40,035 warrants at $3.38 exercise price.","Offering expected to close on or about April 24, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-050338","json":"https://secwatch.observer/filing/0001104659-23-050338.json","markdown":"https://secwatch.observer/filing/0001104659-23-050338.md","text":"https://secwatch.observer/filing/0001104659-23-050338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000110465923050338/0001104659-23-050338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000110465923050338/tm2313709d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:26:04.252501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b78f23e14cbc50ab2fbbda950f316dbfd94e35f9","claim":"Vyome Holdings, Inc entered into Securities Purchase Agreement with a certain institutional investor valued at approximately $2.46 million (effective 2023-04-20).","evidence_excerpt":"On April 20, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 291,395 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) pre-funded warrants to purchase an aggregate of 509,300 shares of Common Stock (the “Pre-funded Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465923050338/0001104659-23-050338-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain institutional investor"},{"label":"Value","value":"approximately $2.46 million"},{"label":"Effective","value":"2023-04-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}